Intellia Therapeutics Inc (NTLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) has a cash flow conversion efficiency ratio of -0.103x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.28 Million) by net assets ($671.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NTLA company net worth for the company's overall valuation and market capitalisation.
Intellia Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Intellia Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Intellia Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intellia Therapeutics Inc ranked by their cash flow conversion efficiency. See Intellia Therapeutics Inc (NTLA) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Urban Transport Planning Center Co. Ltd.
SHE:301091
|
N/A |
|
CS Wind Corp
KO:112610
|
-0.001x |
|
Nichidenbo Corp
TW:3090
|
-0.038x |
|
Del Monte Corporation
NYSE:DMC
|
0.027x |
|
Xinjiang Tianfu Energy Co Ltd
SHG:600509
|
0.047x |
|
Befesa SA
XETRA:BFSA
|
0.044x |
|
Collective Mining Ltd.
NYSE:CNL
|
-0.158x |
|
Maas Group Holdings Ltd
AU:MGH
|
0.040x |
Annual Cash Flow Conversion Efficiency for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Intellia Therapeutics Inc from 2014 to 2025. View NTLA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $671.39 Million | $-348.88 Million | -0.520x | -29.87% |
| 2024-12-31 | $871.96 Million | $-348.88 Million | -0.400x | -6.62% |
| 2023-12-31 | $1.05 Billion | $-394.09 Million | -0.375x | -39.12% |
| 2022-12-31 | $1.24 Billion | $-333.29 Million | -0.270x | -24.69% |
| 2021-12-31 | $1.04 Billion | $-225.03 Million | -0.216x | -128.44% |
| 2020-12-31 | $527.07 Million | $-49.91 Million | -0.095x | +75.25% |
| 2019-12-31 | $269.88 Million | $-103.24 Million | -0.383x | -73.56% |
| 2018-12-31 | $277.92 Million | $-61.26 Million | -0.220x | -1.50% |
| 2017-12-31 | $300.60 Million | $-65.28 Million | -0.217x | -226.19% |
| 2016-12-31 | $209.84 Million | $36.11 Million | 0.172x | +757.44% |
| 2015-12-31 | $67.36 Million | $-1.76 Million | -0.026x | +94.31% |
| 2014-12-31 | $7.57 Million | $-3.48 Million | -0.460x | -- |
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more